The influence of imipramine on dopamine-induced ganglionic inhibition and neurogenic vasodilatation in the dog.
Imipramine potentiates the dopamine-induced inhibition in the paravertebral lumbar ganglia of the dog. Potentiation by imipramine of the dopamine-induced neurogenic vasodilatation in the isolated perfused gracilis muscle, is seen in cross-circulation preparations only, where imipramine is injected into the perfusion circuit of an isolated perfused gracilis muscle, it antagonizes the dopamine-induced neurogenic vasodilatation. When imipramine is injected intravenously into a dog with an autoperfused gracilis muscle, the peripheral antagonism masks the potentiating effect at the ganglionic level, and the dopamine-induced neurogenic vasodilatation is abolished.
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001338:Autonomic Fibers, Postganglionic; D001794:Blood Pressure / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects*; D004285:Dogs; D004298:Dopamine / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D005725:Ganglia, Autonomic / Q000187:drug effects*; D005730:Ganglionic Blockers; D006614:Hindlimb / Q000098:blood supply; D007099:Imipramine / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009433:Neural Inhibition / Q000187:drug effects; D010477:Perfusion; D009435:Synaptic Transmission / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents
D005730:Ganglionic Blockers; D014665:Vasodilator Agents; D007099:Imipramine; D004298:Dopamine